Equitable Cities IV: How the Business Community Impacts City Development

Navigating the infrastructure, land and relationships in construction. Host Adam Morrisey interviews global leaders in the built environment exploring the people, ideas and innovations guiding the construction and civil engineering industries into the future.

 

On this episode of Dirt Work, we concluded our Equity Cities mini-series by discussing the role that the business community plays in the development of our cities with Dallas Regional Chamber (“DRC”) executives Tosha Herron-Bruff and Jared Fitzpatrick. The Dallas Regional Chamber is one of the most established business organizations in the nation and serves as the voice of business and the champion of economic development and growth in the Dallas Region. Tosha and Jared lead the Chamber’s Diversity, Equity, and Inclusion Efforts.

Jared and Tosha discussed the key role that chamber organizations around the country serve in promoting and supporting the business community. The Dallas Chamber works with member companies and regional partners to strengthen our business community by advocating for pro-growth public policies, improving our educational system, attracting talented workers from around the world, and enhancing the quality of life for all. With the DRC’s newly launched initiatives in equity and inclusion, Tosha and Jared support area businesses making contributions to the wellbeing of the region as well as educating other businesses of their responsibility to contribute to building equitable cities. The Chamber aims to make the region a better place for all people to live, work and do business.

The business community benefits their immediate and surrounding areas in many ways:

  1. Attracting talented employees to live in particular regions.
  2. Through the development of districts and/or infrastructure to attract and retain talent, as well as contribute to the livability and business friendliness of the region.
  3. Through the commitment to the welfare of the cities through non-profit, philanthropic, and community-oriented initiatives.

For listeners interested in learning more about the work that the DRC is doing and trends related to diversity, inclusion, and equity, Tosha and Jared recommend keeping up with Dallas Regional Chamber and Dallas Innovates.

Catch Up on Past Episodes of Dirt Work!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More